Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24-month administration of daily teriparatide: comparison among minodronate, raloxifene, and eldecalcitol

The effects of switching daily teriparatide to oral bisphosphonates or denosumab in patients with primary osteoporosis

(2016) Kosuke Ebina et al.   JOURNAL OF BONE AND MINERAL METABOLISM

The importance of assessing the rate of bone turnover and the balance between bone formation and bone resorption during daily teriparatide administration for osteoporosis: a pilot study

(2015) Shinichi Nakatoh   JOURNAL OF BONE AND MINERAL METABOLISM

Overlapping and Continued Alendronate or Raloxifene Administration in Patients on Teriparatide: Effects on Areal and Volumetric Bone Mineral Density-The CONFORS Study

(2014) Christian Muschitz et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Diagnostic criteria for primary osteoporosis: year 2012 revision

(2013) Satoshi Soen et al.   JOURNAL OF BONE AND MINERAL METABOLISM

The safety and effectiveness profile of daily teriparatide in a prospective observational study in Japanese patients with osteoporosis at high risk for fracture: interim report

(2013) Takanori Yamamoto et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Teriparatide vs. Alendronate as a treatment for osteoporosis: Changes in biochemical markers of bone turnover, BMD and quality of life

(2013) Annalisa Panico et al.   MEDICAL SCIENCE MONITOR

Guidelines for the use of bone metabolic markers in the diagnosis and treatment of osteoporosis (2012 edition)

(2012) Yoshiki Nishizawa et al.   JOURNAL OF BONE AND MINERAL METABOLISM

A new active vitamin D3 analog, eldecalcitol, prevents the risk of osteoporotic fractures — A randomized, active comparator, double-blind study

(2011) Toshio Matsumoto et al.   BONE

Effects of teriparatide in postmenopausal women with osteoporosis pre-treated with bisphosphonates: 36-month results from the European Forsteo Observational Study

(2011) F Jakob et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Three years of treatment with minodronate in patients with postmenopausal osteoporosis

(2011) Hiroshi Hagino et al.   JOURNAL OF BONE AND MINERAL METABOLISM

Risk factors for prediction of inadequate response to antiresorptives

(2011) Adolfo Díez-Pérez et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-Month, randomized, placebo-controlled, double-blind and 12-month open-label phases

(2010) Akimitsu Miyauchi et al.   BONE

The bone marker plot: an innovative method to assess bone turnover in women

(2009) C. Bieglmayer et al.   EUROPEAN JOURNAL OF CLINICAL INVESTIGATION

Effects of Teriparatide Treatment and Discontinuation in Postmenopausal Women and Eugonadal Men with Osteoporosis

(2009) Benjamin Z. Leder et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Sequential Treatment of Severe Postmenopausal Osteoporosis After Teriparatide: Final Results of the Randomized, Controlled European Study of Forsteo (EUROFORS)*

(2008) Richard Eastell et al.   JOURNAL OF BONE AND MINERAL RESEARCH

Predictors of falls among postmenopausal women: results from the National Osteoporosis Risk Assessment (NORA)

(2008) E. Barrett-Connor et al.   OSTEOPOROSIS INTERNATIONAL

Effect of daily oral minodronate on vertebral fractures in Japanese postmenopausal women with established osteoporosis: a randomized placebo-controlled double-blind study

(2008) T. Matsumoto et al.   OSTEOPOROSIS INTERNATIONAL